An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens

Bei Wang, Jin He, Chen Liu, Lung Ji Chang

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Viral modification of dendritic cells (DCs) may deliver a "danger signal" critical to the hypo-reactive DCs in cancer patients. Using three highly differentially expressed hepatoma tumor-associated antigens (TAAs): stem cell antigen-2 (Sca-2), glycoprotein 38 (GP38) and cellular retinoic acid binding protein 1 (RABP1), we explored the therapeutic potential of the DCs modified with lentiviral vectors (LVs). Preventive and therapeutic injection of the LV-TAA-DC vaccine into tumor-bearing mice elicited a strong anti-tumor response and extended survival, which was associated with tumor-specific interferon-γ and cytotoxic T cell responses. In vivo elimination of the LV-TAA-DCs by a co-expressed thymidine kinase suicide gene abrogated the therapeutic effect. The modification of DCs with LVs encoding multiple TAAs offers a great opportunity in cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)3477-3489
Number of pages13
JournalVaccine
Volume24
Issue number17
DOIs
StatePublished - Apr 24 2006
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Keywords

  • Dendritic cells
  • Hepatoma
  • Lentiviral vectors
  • Tumor-associated antigen

Fingerprint

Dive into the research topics of 'An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens'. Together they form a unique fingerprint.

Cite this